ILMN
Price
$212.93Alerts
Change
-$1.98 (-0.92%)
Updated
Nov 11 closing price
Capitalization
32.18B
91 days until earnings call
Intraday BUY SELL Signals
LAB
Price
$0.64Alerts
Change
-$0.03 (-4.48%)
Updated
Nov 11 closing price
Capitalization
249.68M
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ILMN vs LAB

ILMN vs LAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ILMN vs. LAB commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Hold and LAB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ILMN with price predictions
Nov 11, 2026

ILMN's Indicator enters downward trend

The Aroon Indicator for ILMN entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator formed such a pattern. In 178 of the 204 cases the stock moved lower. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ILMN as a result. In 74 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

ILMN moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ILMN crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ILMN's RSI Oscillator exited the oversold zone, 15 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 206 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

ILMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.340) is normal, around the industry mean (67.298). P/E Ratio (39.542) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

A.I.Advisor
a Summary for LAB with price predictions
Nov 11, 2026

Momentum Indicator for LAB turns positive, indicating new upward trend

LAB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 81 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LAB just turned positive on November 04, 2026. Looking at past instances where LAB's MACD turned positive, the stock continued to rise in 42 of 54 cases over the following month. The odds of a continued upward trend are 78%.

Following a +11.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 203 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 49 cases where LAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

LAB moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LAB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

LAB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LAB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (4.142). P/E Ratio (2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ILMN vs LAB: Fundamental Ratings
ILMN
LAB
OUTLOOK RATING
1..100
7618
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3150
PRICE GROWTH RATING
1..100
4274
P/E GROWTH RATING
1..100
1177
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LAB's Valuation (50) in the Medical Specialties industry is somewhat better than the same rating for ILMN (83) in the Biotechnology industry. This means that LAB’s stock grew somewhat faster than ILMN’s over the last 12 months.

LAB's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ILMN (100) in the Biotechnology industry. This means that LAB’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's SMR Rating (31) in the Biotechnology industry is in the same range as LAB (50) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to LAB’s over the last 12 months.

ILMN's Price Growth Rating (42) in the Biotechnology industry is in the same range as LAB (74) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to LAB’s over the last 12 months.

ILMN's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for LAB (77) in the Medical Specialties industry. This means that ILMN’s stock grew significantly faster than LAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ILMNLAB
RSI
ODDS (%)
Bullish Trend 1 day ago
56%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ILMN: $212.93 vs. LAB: $0.64)
Brand notoriety: ILMN: Notable vs. LAB: Not notable
ILMN represents the Medical Specialties, while LAB is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: ILMN: 52% vs. LAB: 37%
Market capitalization -- ILMN: $32.18B vs. LAB: $249.68M
ILMN [@Medical Specialties] is valued at $32.18B. LAB’s [@Medical/Nursing Services] market capitalization is $249.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical Specialties] industry is $20.94B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ILMN’s FA Score shows that 2 FA rating(s) are green while LAB’s FA Score has 0 green FA rating(s).

  • ILMN’s FA Score: 2 green, 3 red.
  • LAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ILMN is a better buy in the long-term than LAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ILMN’s TA Score shows that 4 TA indicator(s) are bullish while LAB’s TA Score has 3 bullish TA indicator(s).

  • ILMN’s TA Score: 4 bullish, 6 bearish.
  • LAB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ILMN is a better buy in the short-term than LAB.

Price Growth

ILMN (@Medical Specialties) experienced а -6.01% price change this week, while LAB (@Medical/Nursing Services) price change was +4.38% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.63%, and the average quarterly price growth was -1.72%.

Reported Earning Dates

ILMN is expected to report earnings on Feb 11, 2027.

LAB is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Medical Specialties (-4.83% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Medical/Nursing Services (-2.76% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

LAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, LAB has been loosely correlated with RVTY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LAB jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LAB
1D Price
Change %
LAB100%
-3.31%
RVTY - LAB
44%
Loosely correlated
-0.53%
ILMN - LAB
41%
Loosely correlated
-0.92%
RGEN - LAB
38%
Loosely correlated
-0.78%
A - LAB
37%
Loosely correlated
-0.52%
QGEN - LAB
37%
Loosely correlated
-0.42%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EZJ60.530.63
+1.04%
ProShares Ultra MSCI Japan (EZJ)
OCTB28.180.20
+0.71%
Aptus October Buffer ETF (OCTB)
FDL53.910.16
+0.30%
First Trust Morningstar Dividend Leaders Index Fund (FDL)
HYGH85.110.22
+0.26%
iShares Interest Rate Hedged High Yield Bond ETF (HYGH)
GLDI135.37-1.97
-1.43%
UBS AG ETRACS Gold Shares Covered Call ETNs due February 2, 2033 (GLDI)